Short answer
Pfizer Inc (PFE) filed an 8-K current report with the SEC on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Pfizer announced third-quarter 2026 financial results on November 3, 2026.
Pfizer Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Pfizer announced third-quarter 2026 financial results on November 3, 2026
- Detailed revenue, earnings and guidance information appears in Exhibit 99 accompanying the filing
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $16.6B, flat operationally, while non-COVID revenue grew 7% and launched/acquired products grew 32%
- Adjusted EPS $0.87, flat year over year, despite reported EPS falling 9% to $0.56
- 2026 revenue guidance raised $1.5B at midpoint to $62.0B-$64.0B, signaling stronger commercial execution
- Adjusted EPS guidance raised and narrowed to $2.95-$3.05, despite approximately $0.10 impact from Innovent’s $650M IPR&D charge
- Growth products offset COVID erosion: Eliquis +25%, Padcev +55%, while Paxlovid fell 63% and Comirnaty declined 29% operationally
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Pfizer Inc 8-K filings
Get the next PFE 8-K as it lands
Follow PFE for push alerts, or ask the research agent what this filing means.